Is Nektar Therapeutics (NKTR) Going To Burn These Hedge Funds ?
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th.
Nektar Therapeutics (NKTR)
Market is closed
News
- First
- << Previous
- 21 - 30
- Next >>
Hedge Fund and Insider Trading News: James Dondero, Eddie Lampert, Chris Rokos, ExodusPoint Capital, SkyBridge Capital, Nektar Therapeutics Inc. (NKTR), Oshkosh Corp (OSK), and More
James Dondero doesn’t back down. That’s what helped him build Highland Capital Management into a credit giant that at one point oversaw $40 billion.
Hedge Fund and Insider Trading News: D.E. Shaw, GMT Capital, Citadel Investment Group, Aerie Pharmaceuticals Inc (AERI), Becton Dickinson and Co (BDX), and More
An ongoing legal battle between the high-powered hedge fund D.E. Shaw and a former executive of a portfolio company is shining light on the difficulty of valuing private companies.
Is Nektar Therapeutics (NKTR) A Good Stock To Buy?
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018.
Were Hedge Funds Right About Souring On Nektar Therapeutics (NKTR)?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing.
Nektar Therapeutics (NKTR): Are Hedge Funds Right About This Stock?
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of September...
Three Biotech Investment Ideas from Cormorant Asset Management
The biotech industry is regaining ground it lost in 2016 at full speed.
Market Movers Today: Rovio Entertainment Oyj (ROVVF), Nektar Therapeutics (NKTR), J C Penney Company Inc (JCP), Gap Inc (GPS), and More
Shares in Rovio Entertainment Ltd. (ROVIO.HE) sank further Friday after it warned that competition has intensified while the performance of its new games titles has fallen short of expectations.
Market Movers Today: Tetraphase Pharmaceuticals Inc (TTPH), Twilio Inc (TWLO), Genesco Inc. (GCO), Nektar Therapeutics (NKTR), and More
Tetraphase Pharmaceuticals Inc's Ignite3 trial evaluating the company's lead drug candidate eravacycline for treating complicated urinary tract infections, or cUTIs, failed to ace a late-stage trial.
Nektar Therapeutics (NKTR): Here's What Just Happened
Nektar Therapeutics (NASDAQ:NKTR) is one of the week’s biggest winners in biotech so far, with the company soaring during the Monday session on the release of a fresh round of data from its lead trial...
- First
- << Previous
- 21 - 30
- Next >>
Billionaire Hedge Funds
